|
|
Rexin-G Returns to The Big Apple: Clinical Trials for Pancreatic Cancer and Breast Cancer Open in Manhattan
Wed, 29 Oct 2008, 15:11:24 EDT
Edited by Carly Zander
SAN MARINO, Calif., Oct. 29 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation announced today the expansion of clinical trials using intravenous Rexin-G for pancreatic cancer and breast cancer in Manhattan, New York. Rexin-G is the world's first tumor-targeted genetic medicine that is designed to seek out and destroy both primary tumors and metastatic cancers that have spread throughout the body. Clinical data from on-going studies in Los Angeles, California, indicating dose-dependent tumor control rates and survival benefits with no major toxicity in Rexin-G-treated patients prompted the extension of these clinical trials to the East Coast.
 Rexin-G has gained orphan drug status from the U.S. FDA for three clinical indications: pancreatic cancer, osteosarcoma and soft tissue sarcoma.
The New York clinical trials will be conducted at the Bruckner Oncology Center in Manhattan, New York with Howard W. Bruckner, M.D. as the Principal Investigator. Dr. Bruckner is a board certified medical oncologist who trained at Yale University School of Medicine and performed research at the NIH with specialists and collaborative groups.
Dr. Bruckner is internationally renowned for his work in pancreatic, breast, gastrointestinal, colon, and ovarian cancers and was the first medical oncologist to treat patients with Rexin-G for advanced pancreatic cancer in the United States (Int'l J Oncol 2006). He has served as an Expert Consultant and Safety Monitor for the National Surgical Adjuvant Project for Breast and Bowel Cancers Project (NSABP) sponsored by the National Cancer Institute.
For further information concerning these clinical trials in New York, please go to www.clinicaltrials.gov and search Epeius-sponsored protocols C07-104 and C07-105.
About Epeius Biotechnologies
Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its proprietary targeted delivery systems. To learn more about Rexin-G and Epeius' pipeline of proprietary compounds currently available for outlicensing and clinical development, please visit us at www.epeiusbiotech.com
NEWS SOURCE: Epeius Biotechnologies
Send2Press® is the originating wire service for this story. Terms of Use
THE CONTENT OF THE ABOVE PRESS RELEASE WAS PROVIDED BY THE NEWS SOURCE, WHO IS SOLELY RESPONSIBLE FOR ITS ACCURACY. FOR QUESTIONS ABOUT THIS STORY CONTACT THE NEWS SOURCE AND NOT THIS WEBSITE (SEND2PRESS® NEWSWIRE).
Latest News from Send2Press Newswire:
Additional News on Similar Topics:
Drugs and Pharmaceuticals
|
|
More News from this Company
Reader Resources
Share or Save Story with Bookmarks
Use one of the link buttons, below, to save, share, or bookmark this page for friends and/or future reference.
|
Subscribe Using Popular Social Tools
Use these tools to "subscribe" to the Send2Press Newswire feed of daily news content.
 Follow on Twitter
Choose RSS Feeds by News Topic
|
|
|
Main Send2Press® News Channels
Subscribe to Weekly News Alert
from Send2Press Newswire
Get a free weekly summary of our top newswire stories at the end of each week. Privacy protected and one-click removal in each summary. This is a "double opt-in" subscription, requiring clicking acceptance link in confirmation email.
Privacy Statement
How to Unsubscribe
|
Free News Feeds for Your Blog or Website!
Add news like this to your website with one click.
Simple Javascript copy-paste, or full RSS 2.0,
or Wordpress plugin.
Best of all, it's totally FREE!
Choose from city, state, or industry topics (over 300!). Most main topics updated weekly including business, entertainment and technology news.
CLICK HERE to LEARN MORE
|
|
| |
| | U.S. and World News |
| | Advertising and Marketing |
| | Aerospace and Aviation |
| | Agriculture and Farming |
| | Apple, Mac, iPod and iPhone |
| | Auction and Online Auctions |
| | Auto and Motorsports |
| | Banking and Finance |
| | Beauty Products |
| | Boating, Marine and Maritime |
| | Business |
| | Communication Arts |
| | Company Profiles |
| | Computing |
| | Construction and Building |
| | Corporate Social Responsibility - CSR |
| | Defense and Military |
| | Education and Schools |
| | Electronics |
| | Employment, HR and Outsourcing |
| | Energy, Oil and Gas |
| | Entertainment |
| | Environment and Ecology |
| | Facilities and Building Maintenance |
| | Family, Parenting and Children |
| | Food and Beverages |
| | General Editorial |
| | Global Aid and Relief |
| | Government |
| | Green Business |
| | Health, Diet and Fitness |
| | Home and Garden |
| | HVAC Heating and Cooling |
| | Insurance |
| | Internet and Websites |
| | Jewelry and Diamond |
| | Legal and Law |
| | Manufacturing |
| | Medical |
| | Alternative Medicine |
| | Biotechnology |
| | Cosmetic Surgery |
| | Dentistry |
| | Devices and Research |
| | Disabilities and 508 Compliance |
| | Drug Rehabilitation |
| | Drugs and Pharmaceuticals |
| | Fertility and IVF |
| | Hospitals and Nursing |
| | Long Term Care |
| | Medical and Health Products |
| | Medical Business Services |
| | Ophthalmology and Vision |
| | Private Practice and Medical Groups |
| | Surgery and Neurotechnology |
| | Mining and Metals |
| | Mortuary and Cemetery |
| | NonProfit and Charities |
| | Plastics and Composites |
| | Police, Fire and Rescue |
| | Real Estate |
| | Regional Events |
| | Religion and Churches |
| | Restaurant, Hotel and Hospitality |
| | Safety and Security Solutions |
| | Sciences |
| | Sports and Activities |
| | Stamps, Coins and Collectables |
| | Taxes and Accounting |
| | Telecommunications and VoIP |
| | Theme Parks and Attractions |
| | Trade Shows, Fairs and Expos |
| | Transportation |
| | Travel and Tourism |
| | US and World History |
| | Veterinary and Pets |
| |
| | U.S. State Newswires |
| | Alabama Business |
| | Alaska Business |
| | Arizona Business |
| | California Business |
| | Colorado Business |
| | Connecticut Business |
| | Delaware Business |
| | Florida Business |
| | Georgia Business |
| | Hawaii Business |
| | Idaho Business |
| | Illinois Business |
| | Indiana Business |
| | Iowa Business |
| | Kansas Business |
| | Kentucky Business |
| | Louisiana Business |
| | Maine Business |
| | Maryland Business |
| | Massachusetts Business |
| | Michigan Business |
| | Minnesota Business |
| | Mississippi Business |
| | Missouri Business |
| | Montana Business |
| | Nebraska Business |
| | Nevada Business |
| | New Hampshire Business |
| | New Jersey Business |
| | New Mexico Business |
| | New York Business |
| | North Carolina Business |
| | Ohio Business |
| | Oklahoma Business |
| | Oregon Business |
| | Pennsylvania Business |
| | Puerto Rico Business |
| | South Carolina Business |
| | South Dakota Business |
| | Tennessee Business |
| | Texas Business |
| | Utah Business |
| | Vermont Business |
| | Virginia Business |
| | Washington D.C. Business |
| | Washington State Business |
| | West Virginia Business |
| | Wisconsin Business |
| |
| | Video News Releases |
| |
| | World Newswires |
| | Australia Business |
| | Brazil Business |
| | Canada Business |
| | China Business |
| | Germany Business |
| | Italy Business |
| | Spain Business |
| | United Kingdom |
|
Terms of Use and License
This "article" version of the issued press release is Copr. © 1983-2009 Neotrope/Send2Press. You may freely link to this article version of the press release or may use the release text as the basis for an original article or news posting. If the content is copied verbatim via a scraping or copy/paste method, the news item must be properly "attributed" to Send2Press® Newswire as the originating wire service for this story.
|
DISCLAIMER: the above press release content is believed accurate but not guaranteed, and is based on business news supplied by the source. The noted source is solely responsible for its accuracy. Financial/Stock news may contain forward looking statements. Neotrope/Send2Press (this website) makes no claims of accuracy or suitability for any purpose. Any opinions expressed by representatives of company(s) mentioned in news and profiles are solely those of the person indicated, and do not reflect any opinion or policy of Neotrope® or Send2Press. Your use of any information contained herein is done solely at your own risk, and you are fully responsible for using any information herein, or on sites mentioned or linked to in the article. All trademarks acknowledged.
REFERENCES: Rexin-G Returns to The Big Apple: Clinical Trials for Pancreatic Cancer and Breast Cancer Open in Manhattan, Epeius Biotechnologies, Rexin-G for pancreatic cancer and breast cancer, orphan drug status from the U.S. FDA, pharma, clinical trials, Howard W. Bruckner, M.D. as the Principal Investigator, biopharmaceutical company, Oct 29, 2008.
|
|
|
Search Send2Press.com:
Google
Reddit
Diigo
Delicious
Yahoo!
Digg
Blinklist
Blogmarks
Mixx
Facebook
Newsvine
